Although stability testing programs for small-molecule drugs and biologics are often perceived as similar, stability programs for biologics are far more complex.
Meg Rivers
Advertisement
Meg Rivers is the former senior editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.
Articles by Meg Rivers
Alternatives to animal testing and in-vivo assays are occurring as a result of recent scientific advances.
Low- and middle-income countries are at the greatest risk of receiving substandard and falsified COVID-19 vaccines.
The COVID-19 pandemic has further impacted ongoing drug shortage issues; essential action is needed to avoid repeating previous mistakes.
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA, Duke University Planning Epinephrine Access Workshop for December
2
FAQ: Key AI Applications in Drug Development
3
Industry Expert Panel Weighs CNPV Benefits, Risks, and Readiness: Part II
4
Industry Expert Panel Weighs CNPV Benefits, Risks, and Readiness: Part I
5
